In this issue:
MM5 trial confirms superior survival with maintenance duration extended beyond achievement of CR
CENTAURUS assesses daratumumab monotherapy for high-risk SMM
Real-world study of primary refractory MM finds ASCT to be superior to bridging therapy
CANDOR shows improved outcomes with the addition of daratumumab to carfilzomib/dexamethasone
Long-term results from CASTOR confirm the benefit of daratumumab with Vd for RRMM
POLLUX shows a sustained benefit to triplet daratumumab/lenalidomide/ dexamethasone
Tandem autologous/allogeneic transplantation for MM
Thrombosis in patients with myeloma treated in Myeloma IX and Myeloma XI
“Direct to Drug” screening as a precision medicine tool in MM
Please login below to download this issue (PDF)